NCT02393690 - Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 4, 2015

Primary Completion Date

July 17, 2020

Study Completion Date

December 31, 2023

Conditions

Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage IV Thyroid Gland Follicular Carcinoma AJCC v7Stage IV Thyroid Gland Papillary Carcinoma AJCC v7Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7

Interventions

RADIATION

Iodine I-131

Given PO

OTHER

Placebo Administration

Given PO

DRUG

Selumetinib

Given PO

Trial Locations (11)

10065

Memorial Sloan Kettering Cancer Center, New York

20007

MedStar Georgetown University Hospital, Washington D.C.

27710

Duke University Medical Center, Durham

37232

Vanderbilt University/Ingram Cancer Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic in Rochester, Rochester

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado Hospital, Aurora

92093

UC San Diego Moores Cancer Center, La Jolla

92663

Hoag Memorial Hospital, Newport Beach

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER